Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company’s web site at www.vyteris.com.
- 18 years ago
QualityStocks
Vyteris, Inc. (OTC BB: VYTR)
Tags Rodman & Renshaw
Related Post
-
Greenland Mines Ltd. (NASDAQ: GRML) Advances World-Class Palladium Deposit with Major Resource Upgrade
The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian…
-
Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Is Building a Modern Public Safety Platform by Integrating Tools, Training and Policy
Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools,…